Sistema de Salut de Catalunya
Institut Català de la Salut
[Altabás-González I, Pego-Reigosa JM] Department of Rheumatology, Complexo Hospitalario Universitario de Vigo, Galicia Sur Health Research Institute, Rheumatology and Inmuno-Mediated Diseases Reasearch Group (IRIDIS), Vigo, Spain. [Mouriño C, Jiménez N] Department of Rheumatology, Galicia Sur Health Research Institute, Rheumatology and Inmuno-Mediated Diseases Reasearch Group (IRIDIS), Vigo, Spain. [Hernández-Martín A] Department of Rheumatology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Spain. [Casafont-Solé I] Department of Rheumatology, Germans Trias i Pujol University Hospital, LCMN, Germans Trias i Pujol Research Institute (IGTP), Barcelona, Spain. [Cortés-Hernández J, Penzo E] Grup de Recerca en Reumatologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2025-03-07T12:14:44Z
2025-03-07T12:14:44Z
2024
2025-01
Effectiveness; Remission; Systemic lupus erythematosus
Efectividad; Remisión; Lupus eritematoso sistémico
Efectivitat; Remissió; Lupus eritematós sistèmic
Objectives: To provide an overview on the current use of belimumab (BLM) in SLE patients in clinical practice and to examine its efficacy in terms of standardized outcomes, drug survival, as well as patient and safety profiles. Methods: A longitudinal retrospective multicenter cohort including SLE patients treated with BLM at 18 Spanish centers. Data was collected upon initiation of BLM, at 6 and 12 months after initiation, and at the last recorded visit. Changes in SLEDAI-2K, the proportion of patients who achieved LLDAS and DORIS 2021, and number of flares were compared between visits. Changes in damage, glucocorticoids use and employment status pre-BLM and post-BLM were also assessed. Results: A total of 324 patients were included with a mean follow-up of 3.8 (±2.7) years. LLDAS was attained by 45.8%, 62% and 71% of patients, and DORIS by 24%, 36.2% and 52.5% on successive visits, respectively. A total of 27.2% of patients were in DORIS ≥50% of the visits and 46% in LLDAS-50. Flares and number of flares were significantly lower one year after treatment with BLM and no changes in damage accrual were observed. Mean (±SD) prednisone dose was significantly reduced over time, with 70 (24%) patients discontinuing GC. Conclusion: Our study not only demonstrates belimumab's efficacy in attaining treat-to-target goals in SLE patients, but also confirms its GC-sparing effect, and its prevention of flares and organ damage accrual.
Funding was received from GlaxoSimthKline to support the statistical analysis of this work.
Article
Published version
English
Avaluació de resultats (Assistència sanitària); Anticossos monoclonals - Ús terapèutic; Lupus eritematós sistèmic - Tractament; Glucocorticoides - Ús terapèutic; Medicaments immunosupressors - Tractament; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome; DISEASES::Skin and Connective Tissue Diseases::Connective Tissue Diseases::Lupus Erythematosus, Systemic; Other subheadings::Other subheadings::Other subheadings::/drug therapy; CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized; Other subheadings::Other subheadings::/therapeutic use; CHEMICALS AND DRUGS::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormones::Adrenal Cortex Hormones::Glucocorticoids; CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Immunologic Factors::Immunosuppressive Agents; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento; ENFERMEDADES::enfermedades de la piel y tejido conjuntivo::enfermedades del tejido conjuntivo::lupus eritematoso sistémico; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia; COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales; Otros calificadores::Otros calificadores::/uso terapéutico; COMPUESTOS QUÍMICOS Y DROGAS::hormonas, sustitutos de hormonas y antagonistas de hormonas::hormonas::hormonas de la corteza suprarrenal::glucocorticoides; COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::efectos fisiológicos de los fármacos::factores inmunitarios::inmunosupresores
Oxford University Press
Rheumatology;64(1)
https://doi.org/10.1093/rheumatology/kead696
Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
Articles científics - VHIR [1655]
